LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 3 von insgesamt 3

Suchoptionen

  1. Artikel: Dois regimes monetários

    Noronha, Luis Eduardo Pitta de

    Oikos : revista de economia heterodoxa Bd. V.2006=Nr. 6, S. 66-86

    uma análise comparativa do período pós plano real

    2006  

    Verfasserangabe Luis Eduardo Pitta de Noronha
    Sprache Portugiesisch
    Umfang graph. Darst.
    Erscheinungsort Rio de Janeiro
    Dokumenttyp Artikel
    ZDB-ID 2113724-9
    Datenquelle ECONomics Information System

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  2. Artikel ; Online: CANadian CAnagliflozin REgistry: Patient-Reported Outcomes of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Canadian Clinical Practice.

    Woo, Vincent / Bell, Alan / Clement, Maureen / Noronha, Luis / Tsoukas, Michael A / Camacho, Fernando / Traina, Shana / Georgijev, Natasha / Rose, Jennifer B / Sorabji, Delna / Bajaj, Harpreet S

    Canadian journal of diabetes

    2019  Band 43, Heft 7, Seite(n) 464–471

    Abstract: Objectives: To describe patient-reported outcomes (PROs) after initiation of treatment with canagliflozin (CANA) for type 2 diabetes mellitus (T2DM) in a real-world Canadian setting.: Methods: CANadian CAnagliflozin REgistry (CanCARE) is a ... ...

    Abstract Objectives: To describe patient-reported outcomes (PROs) after initiation of treatment with canagliflozin (CANA) for type 2 diabetes mellitus (T2DM) in a real-world Canadian setting.
    Methods: CANadian CAnagliflozin REgistry (CanCARE) is a prospective, observational, single-arm, real-world Canadian study of the effectiveness and safety of CANA for the treatment of T2DM in 527 subjects. PRO measures were collected in CanCARE using the Current Health Satisfaction Questionnaire (CHES-Q) at baseline and after 3, 6 and 12 months of CANA treatment to examine patient satisfaction regarding weight and overall health. Associations between changes in satisfaction with weight, systolic blood pressure (SBP) and glycated hemoglobin (A1C) levels were also investigated.
    Results: Proportion of patients satisfied with their body weight and overall health increased from 22.1% and 26.9% at baseline to 32.4% and 49.2% after 12 months of CANA treatment, respectively. Satisfaction rates also increased on CHES-Q domains representing physical and emotional health. Correlations were found between improvement in satisfaction with body weight and weight loss (r=-0.29; p<0.01) and between improvements in satisfaction with overall health and weight loss (r=-0.13; p=0.03) and SBP (r=-0.17; p<0.01), but not with changes in A1C level.
    Conclusions: Treatment with CANA is associated with improvements in satisfaction with body weight and overall health, which may be important drivers of patient self-management and hold the potential to positively influence long-term outcomes in T2DM.
    Mesh-Begriff(e) Blood Glucose/analysis ; Body Weight ; Canada ; Canagliflozin/therapeutic use ; Diabetes Mellitus, Type 2/drug therapy ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Patient Reported Outcome Measures ; Practice Patterns, Physicians'/statistics & numerical data ; Prognosis ; Prospective Studies ; Registries/statistics & numerical data ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Surveys and Questionnaires ; Weight Loss
    Chemische Substanzen Blood Glucose ; Sodium-Glucose Transporter 2 Inhibitors ; Canagliflozin (0SAC974Z85)
    Sprache Englisch
    Erscheinungsdatum 2019-04-16
    Erscheinungsland Canada
    Dokumenttyp Journal Article ; Observational Study
    ISSN 2352-3840
    ISSN (online) 2352-3840
    DOI 10.1016/j.jcjd.2019.04.004
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  3. Artikel ; Online: CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice.

    Woo, Vincent / Bell, Alan / Clement, Maureen / Noronha, Luis / Tsoukas, Michael A / Camacho, Fernando / Traina, Shana / Georgijev, Natasha / Culham, Matthew D / Rose, Jennifer B / Rapattoni, Wally / Bajaj, Harpreet S

    Diabetes, obesity & metabolism

    2018  Band 21, Heft 3, Seite(n) 691–699

    Abstract: Aim: There is limited information concerning the effects of canagliflozin (CANA), a sodium-glucose co-transporter 2 inhibitor (SGLT2i) in a real-world clinical setting in Canada. CanCARE is a 12-month, prospective, observational analysis to demonstrate ... ...

    Abstract Aim: There is limited information concerning the effects of canagliflozin (CANA), a sodium-glucose co-transporter 2 inhibitor (SGLT2i) in a real-world clinical setting in Canada. CanCARE is a 12-month, prospective, observational analysis to demonstrate the effectiveness and safety of CANA in usual clinical practice in Canada.
    Materials and methods: SGLT2i-naïve adult patients with type 2 diabetes mellitus (T2DM) (n = 527) on a stable antihyperglycemic agent (AHA) regimen with glycated hemoglobin (A1C) ≥ 7%, an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m
    Results: Significant improvement from baseline in mean HbA1c levels were observed at 6 months (-0.90%; 95% CI, -1.02, -0.78) and at 12 months (-1.04%; 95% CI, -1.15, -0.92), regardless of duration of diabetes or background AHA treatment regimen. Similarly, significant decreases in systolic blood pressure (-4.65 mm Hg); body weight (-3.24 kg), waist circumference (-2.91 cm) and body mass index (-1.15 kg/m
    Conclusion: CANA provided sustained clinically meaningful improvements in cardiometabolic parameters in this study in a real-world setting, confirming findings from randomized controlled trials.
    Mesh-Begriff(e) Adult ; Aged ; Canada ; Canagliflozin/adverse effects ; Canagliflozin/therapeutic use ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/epidemiology ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Electronic Health Records/statistics & numerical data ; Female ; General Practice/statistics & numerical data ; Humans ; Male ; Middle Aged ; Registries ; Treatment Outcome
    Chemische Substanzen Canagliflozin (0SAC974Z85)
    Sprache Englisch
    Erscheinungsdatum 2018-12-05
    Erscheinungsland England
    Dokumenttyp Journal Article ; Multicenter Study ; Observational Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 1454944-x
    ISSN 1463-1326 ; 1462-8902
    ISSN (online) 1463-1326
    ISSN 1462-8902
    DOI 10.1111/dom.13573
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 5442: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang